指南与共识流行病学与生物统计临床试验与 GCP

肿瘤学中的患者偏好试验:范围综述与报告建议

Patient preference trials in oncology: a scoping review and recommendations on reporting.
指南 / 共识 · J Clin Epidemiol · 2025-05-23

该范围综述纳入44项肿瘤学患者偏好试验(PPT),其中34项旨在评估干预效果(24项已完成试验、10项方案)。最常报告的选用PPT设计的理由是认为随机对照试验(RCT)不可行(17项,50%),18项(53%)进行了基线协变量调整,24项已完成试验中有14项报告了设计时未预料到的组间分配比例不等。作者建议未来PPT应考虑并报告偏好分配导致的混杂偏倚和组间样本量不等问题。

要点

  • 共识别44项肿瘤学PPT,其中34项评估干预效果,24项为已完成试验、10项为方案。
  • 选用PPT设计的最常见理由是认为RCT不可行(17项,50%)。
  • 24项已完成试验中14项报告了设计时未预料到的组间分配比例不等。

核心结论

  • 该综述识别了肿瘤学PPT的若干挑战,未来PPT应考虑并报告偏好分配导致的混杂偏倚和组间样本量不等问题,这些方面对研究的有效性和统计效能至关重要。

研究设计与样本

  • 范围综述,纳入所有部分或全部患者按偏好分配治疗组的肿瘤学前瞻性研究,共识别44项PPT,其中34项旨在评估干预效果并接受详细审查(24项已完成试验、10项方案)。

主要发现

  • 44项PPT中34项(77%)旨在评估干预效果。
  • 34项有效性PPT中24项(71%)为已完成试验,10项为方案。
  • 选用PPT设计的最常见理由是认为RCT不可行(17项,50%)。
  • 18项(53%)研究进行了基线协变量调整。
  • 24项已完成试验中14项报告了设计时未预料到的组间分配比例不等。

关键数值与推荐

  • 未来PPT应考虑并报告偏好分配导致的混杂偏倚和组间样本量不等问题。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The feasibility, generalizability, and validity of randomized controlled trials (RCTs) may be compromised when patients have preferences for specific trial arms. The patient preference trial (PPT) design, which assigns at least a subset of the patients based on their preference rather than randomization, has been proposed as an alternative. The aim of this review was to provide an overview of the application of the PPT design in oncological research, with a particular focus on PPTs designed to assess the effectiveness of an intervention and provide recommendations on reporting. STUDY DESIGN AND SETTING: We performed a scoping review including all prospective oncological studies where trial arm allocation for part or all of the patients was based on patients' preferences. Retrieved information included research objectives, motivation for the design choice, baseline covariate adjustments, and sample size calculations. RESULTS: We identified 44 PPTs, of which 34 (77%) aimed to investigate intervention effectiveness and were reviewed in more detail. Of these 34 effectiveness PPTs, 24 (71%) studies were completed trials, while 10 were protocols. The most frequently indicated rationale behind opting for the PPT design was the perceived infeasibility of an RCT (17 [50%] studies). Baseline covariate adjustment was performed in 18 (53%) studies. Fourteen out of 24 completed trials reported an unequal allocation ratio across trial arms not anticipated during the design. CONCLUSION: This review identified several challenges for PPTs in oncology. Future PPTs should take bias due to confounding and unequal group sizes arising from the preferential allocation into account and report on these issues, as these aspects are crucial for the validity and statistical power of the study.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Kamp D, Kessels R, Haj Mohammad N, et al. Patient preference trials in oncology: a scoping review and recommendations on reporting. J Clin Epidemiol. 2025. PMID: 40414365. doi:10.1016/j.jclinepi.2025.111837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。